Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which IV drug tames a racing heart in AFib faster? a Head-to-Head trial

NCT ID NCT07706075

Disease control Sponsor: Muhammad Ali Javed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This trial compares two standard IV medicines—verapamil and metoprolol—to see which controls rapid heart rate better in adults with atrial fibrillation who are otherwise stable. Patients receive one of the drugs in the emergency department, and their heart rate, blood pressure, and oxygen levels are monitored for 30 minutes. The goal is to find which drug works faster and more safely, helping doctors make evidence-based choices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intravenous verapamil or intravenous metoprolol
What this could lead to
If one drug works faster or more safely, it could help doctors choose the best treatment for atrial fibrillation with rapid heart rate in the emergency room.
What could go wrong
This is a small, single-center trial, so results may not apply to all patients. Both drugs can cause low blood pressure or slow heart rate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 years and above presenting to the Emergency Department * Confirmed diagnosis of atrial fibrillation with rapid ventricular response (heart rate ≥110 bpm) on 12-lead ECG * Hemodynamically stable at the time of enrollment (systolic blood pressure ≥90 mmHg, no shock, no acute pulmonary edema) * Willingness to provide written informed consent Exclusion Criteria: * Hemodynamic instability, cardiogenic shock, or acute decompensated heart failure * Known pre-excitation syndrome (e.g., Wolff-Parkinson-White syndrome) on baseline ECG * Severe left ventricular systolic dysfunction (ejection fraction less than 30%) as determined by echocardiography * Known hypersensitivity or contraindication to verapamil or metoprolol * Patients already taking rate control agents (beta-blockers, calcium channel blockers, or digoxin) in the last 24 hours * Major bradycardia (heart rate less than 50 bpm) or AV block (second or third degree) on baseline ECG * Active bronchospasm or severe obstruction of pulmonary disease * Severe hepatic impairment (Child-Pugh Class C) or acute renal failure (eGFR \<15 mL/min/1.73 m²) * Pregnancy or breastfeeding * Inability to give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF) Atrial fibrillation with rapid ventricular response

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.